Business
CiRT highlighted at ESMO 2022 presentation
CiRT highlighted at ESMO 2022 presentation.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n Oxford BioDynamics Announces Collaborative Late-Breaking Podium Presentation at the European Society of Medical Oncology (ESMO) 2022 Congress\n \n \n \n \n \n \n \n \n ·\n \n The European Society of Medical Oncology (ESMO) 2022 Congress is one of the most prestigious oncology conferences in the world\n \n \n \n ·\n \n Presentation title: \"Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)\", which included OBD's EpiSwitch® platform technology\n \n \n \n ·\n \n Presenter: Professor Thomas Powles, MBBS, MD, MRCP, Director of Barts Cancer Centre, St. Bartholomew's Hospital\n \n \n \n ·\n \n Timing of presentation: 11:10am CEST, 10 September 2022\n \n \n \n ·\n \n The OBD team will also have an exhibition at booth #419 in Hall 7 (level 7.2) and will be discussing the features of the EpiSwitch® platform and Checkpoint Inhibitor Response Test (CiRT)\n \n \n \n \n \n \n \n Oxford, UK - 6 September, 2022\n \n -\n Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces its flagship clinical platform will be highlighted in a late-breaking podium presentation at the upcoming European Society of Medical Oncology (ESMO) Annual Congress, which is being held September 9 - 13, 2022, at the Paris Expo Porte de Versailles in Paris, France.\n \n \n The presentation, titled \"Genomic biomarkers in peripheral blood from patients enrolled in the JAVELIN Bladder 100 trial of avelumab first-line maintenance in advanced urothelial carcinoma\" will be delivered by renowned oncology specialist Professor Thomas Powles,\n MBBS, MD, MRCP,\n Director of Barts Cancer Centre at St. Bartholomew's Hospital. Collaborators from pharma and global medical cancer centers also serve as co-authors on the paper, including Dana-Farber Cancer Institute (MA, USA), Barts Cancer Institute (UK), Fred Hutchinson Cancer Center (WA, USA), Princess Margaret Cancer Center (ON, CA), and Meyer Cancer Center (NY, USA). This late-breaking abstract reflects novel research findings with implications for clinical practice. Further details of the study are under data embargo until September 8th, 2022.\n \n \n...